Loading clinical trials...

18F-Pentixafor PET in Hematologic Malignancies | Clinical Trials | Clareo Health

RECRUITING

18F-Pentixafor PET in Hematologic Malignancies

Prospective Clinical Study of 18F-Pentixafor PET Imaging in Hematologic Malignancies

NCT07122674•First Affiliated Hospital of Zhejiang University

Summary

The aim of this study is to evaluate the efficacy of 18F-Pentixafor PET imaging in the diagnosis, staging and response evaluation of hematological malignancies.

Detailed Description

18F-FDG PET imaging based on the principle of glucose metabolism imaging is currently dominant in the staging and efficacy evaluation of lymphoma, but it is not suitable for a wider range of hematological tumors. Chemokine receptor 4 (CXCR-4) is a G protein-coupled receptor, which is overexpressed in a variety of hematological malignancies (MM, leukemia, lymphoma, etc.). It promotes tumor growth, invasion, metastasis, drug resistance, immune escape, and is associated with poor prognosis of tumors. 18Fluorine18 (18F)-NOTA-Pentixafor (18f-pentixafor) is a novel specific molecular probe targeting CXCR-4. Compared with 68Ga-Pentixafor, 18f-pentixafor has a longer half-life. More patients can be used in one synthesis, and the image quality is better and the spatial resolution is higher. Patients can undergo PET at 1 h after injection without special preparation. The aim of this study is to evaluate the performance of 18F-Pentixafor PET imaging in the diagnosis, staging, and response evaluation of hematological malignancies. Patients with suspected or histologically confirmed hematological malignancies will be enrolled in this study.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age of 18-80 years old, both sexes, with behavioral capacity;
•2. patients with suspected or confirmed hematological malignancies;
•3. 18F-FDG PET or other imaging examinations should be performed according to the treatment plan;
•4. For suspected patients, biopsy or needle biopsy is expected to obtain pathological results;
•5. Can provide informed consent, can understand and comply with the requirements of the study.

Exclusion Criteria

•1. pregnant and lactating women;
•2. patients with fear or radiophobia, or with mental disorder or primary affective disorder;
•3. received ionizing radiation outside the scope of this study for clinical medical or scientific research purposes within the past year, resulting in an annual radiation exposure dose exceeding 50 mSv;
•4. received investigational drugs or devices of uncertain efficacy or safety within 1 month;
•5. Any condition that the chairpersons of the study consider that any link related to the study may cause harm or have potential harm.

Locations (1)

The First Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Key Dates

Start Date

July 1, 2025

Primary Completion Date

December 1, 2028

Completion Date

December 1, 2029

Last Updated

August 14, 2025

Enrollment

100

ESTIMATED participants

Conditions

Hematological Malignancies

Interventions

18F-Pentixafor

DRUG

Contacts

Peipei Wang, MD

CONTACT

86 18511395988 wpp199411@163.com

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

NCT02269592

Monoclonal Gammopathy of Undetermined Significance (MGUS)Myelodysplastic Syndromes+6 more

View study

RECRUITING

Cord Blood Transplantation With Myeloablative Conditioning and Post-transplant Cyclophosphamide (COmPACt Study)

NCT03802773

Cord Blood TransplantationHematological Malignancies

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 14, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

18F-Pentixafor PET in Hematologic Malignancies

Inclusion Criteria

Exclusion Criteria

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Cord Blood Transplantation With Myeloablative Conditioning and Post-transplant Cyclophosphamide (COmPACt Study)

A Study Evaluating the Value of 68Ga-Pentixafor PET Imaging in the Staging of Hematological Tumor, and Comparing It with 18F-FDG PET/CT Imaging

Efficacy of Inhaled Aromatherapy on Nausea and Vomiting in Hematological Malignancies

Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies

Cologne Cohort of Neutropenic Patients (CoCoNut)